Skip to main content
SpringerLink
Log in

No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas

  • Laboratory Investigation
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) have been identified in approximately 70–80 % of astrocytomas and oligodendrogliomas of WHO grades II and III, and in secondary glioblastomas. In addition, a low incidence of IDH2 mutations has been detected in these tumors, and the occurence of IDH1 and IDH2 mutations is mutually exclusive. For patients with anaplastic gliomas and glioblastomas with IDH1 mutations, overall survival was significantly longer than for patients with wild-type tumours. However, the prognostic value of IDH1 in low-grade gliomas remains ambiguous. IDH1 codon 132 and IDH2 codon 172 mutation status were determined by direct sequencing for a retrospective series of 100 patients with histologically diagnosed Astrocytomas WHO Grad II (A II), and investigated for association with patient outcome. For the patient cohort analysed, median progression-free survival (PFS) was 44.6 months (95 %-CI 1.0–267.0), time to progression (median time to malignant progression (TtMP) was 74.9 months (95 %-CI 1.6–236.2), and median overall survival (OS) was 81.4 months (95 %-CI 5.5–274.8). IDH1 mutations were identified in 79 % of the patients. IDH2 mutations were not observed. Univariate and multivariate analysis revealed no association between IDH1 mutation status and PFS, TtMP, and OS. Furthermore, there were no significant differences regarding PFS, TtMP, and OS between patients with and without IDH1 mutations who did not receive adjuvant treatment. The prognostic value of IDH1 mutations in low-grade astrocytomas is rather low compared with that in high-grade gliomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Louis DN, International Agency for Research on Cancer (2007) WHO classification of tumours of the central nervous system. World Health Organization classification of tumours, 4th edn. International Agency for Research on Cancer, Lyon

  2. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20(8):2076–2084

    Article  PubMed  Google Scholar 

  3. Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ (2002) Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 8(5):1117–1124

    PubMed  CAS  Google Scholar 

  4. Ständer M, Peraud A, Leroch B, Kreth FW (2004) Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis. Cancer 101(5):1028–1035

    Article  PubMed  Google Scholar 

  5. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812. doi:10.1126/science.1164382

    Article  PubMed  CAS  Google Scholar 

  6. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6):597–602. doi:10.1007/s00401-008-0455-2

    Article  PubMed  CAS  Google Scholar 

  7. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174(4):1149–1153. doi:10.2353/ajpath.2009.080958

    Article  PubMed  CAS  Google Scholar 

  8. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773. doi:10.1056/NEJMoa0808710

    Article  PubMed  CAS  Google Scholar 

  9. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118(4):469–474. doi:10.1007/s00401-009-0561-9

    Article  PubMed  Google Scholar 

  10. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C (2009) Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 118(3):401–405. doi:10.1007/s00401-009-0550-z

    Article  PubMed  CAS  Google Scholar 

  11. Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, Stein R, Reifenberger G, Pietsch T, von Deimling A, Loeffler M, Weller M (2011) Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 17(13):4588–4599. doi:10.1158/1078-0432.CCR-10-3194

    Article  PubMed  CAS  Google Scholar 

  12. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Vital A, Mariani L, Stawski R, Watanabe T, De Girolami U, Kleihues P, Ohgaki H (2010) Molecular classification of low-grade diffuse gliomas. Am J Pathol 177(6):2708–2714. doi:10.2353/ajpath.2010.100680

    Article  PubMed  Google Scholar 

  13. Labussiere M, Idbaih A, Wang XW, Marie Y, Boisselier B, Falet C, Paris S, Laffaire J, Carpentier C, Criniere E, Ducray F, El Hallani S, Mokhtari K, Hoang-Xuan K, Delattre JY, Sanson M (2010) All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74(23):1886–1890. doi:10.1212/WNL.0b013e3181e1cf3a

    Article  PubMed  CAS  Google Scholar 

  14. Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhtari K, Wang XW, Loundou A, Chapon F, Pineau S, Ouafik L, Chinot O, Figarella-Branger D (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120(6):719–729. doi:10.1007/s00401-010-0777-8

    Article  PubMed  Google Scholar 

  15. Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, Peraud A, Kreth FW (2011) IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer. doi:10.1002/cncr.26298

  16. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27(25):4150–4154. doi:10.1200/JCO.2009.21.9832

    Article  PubMed  CAS  Google Scholar 

  17. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the german glioma network. J Clin Oncol 27(34):5743–5750. doi:10.1200/JCO.2009.23.0805

    Article  PubMed  CAS  Google Scholar 

  18. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27(35):5874–5880. doi:10.1200/JCO.2009.23.6497

    Article  PubMed  CAS  Google Scholar 

  19. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16(5):1597–1604. doi:10.1158/1078-0432.CCR-09-2902

    Article  PubMed  Google Scholar 

  20. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120(6):707–718. doi:10.1007/s00401-010-0781-z

    Article  PubMed  Google Scholar 

  21. Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, Harter PN, Jeibmann A, von Deimling A (2011) Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol 121(2):241–252. doi:10.1007/s00401-010-0770-2

    Article  PubMed  Google Scholar 

  22. Hartmann C, von Deimling A (2009) Molecular pathology of oligodendroglial tumors. Recent Results Cancer Res 171:25–49. doi:10.1007/978-3-540-31206-2_2

    Article  PubMed  Google Scholar 

  23. Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ (2009) IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73(21):1792–1795. doi:10.1212/WNL.0b013e3181c34ace

    Article  PubMed  CAS  Google Scholar 

  24. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, Collins VP (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11(4):341–347. doi:10.1215/15228517-2009-025

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Jochen Meyer and Kerstin Lindenberg for their excellent technical assistance.

Conflict of interest

All authors declare that they have no conflict of interest. No author has a financial relationship with the organization that sponsored the research.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Ruprecht-Karls-Universität Heidelberg, 69120, Heidelberg, Germany

    Rezvan Ahmadi, Christine Dictus, Christel Herold-Mende & Andreas Unterberg

  2. Department of Neurosurgery, Universität Göttingen, 37075, Göttingen, Germany

    Florian Stockhammer

  3. Division for Molecular Genetics, German Cancer Research Center, 69120, Heidelberg, Germany

    Natalia Becker

  4. Department of Neurosurgery, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany

    Katarina Hohlen & Martin Misch

  5. Clinical Cooperation Unit Neuropathology, German Cancer Research Center, 69120, Heidelberg, Germany

    Arne Christians, David Capper & Andreas von Deimling

  6. Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-Universität Heidelberg, 69120, Heidelberg, Germany

    David Capper & Andreas von Deimling

  7. Department of Neurooncology, Ruprecht-Karls-Universität Heidelberg, 69120, Heidelberg, Germany

    Wolfgang Wick

  8. Department of Neuropathology, Institute of Pathology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany

    Christian Hartmann

Authors
  1. Rezvan Ahmadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Florian Stockhammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Natalia Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katarina Hohlen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martin Misch
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Arne Christians
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christine Dictus
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christel Herold-Mende
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. David Capper
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Andreas Unterberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Andreas von Deimling
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Wolfgang Wick
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Christian Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Hartmann.

Additional information

Rezvan Ahmadi and Florian Stockhammer contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahmadi, R., Stockhammer, F., Becker, N. et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J Neurooncol 109, 15–22 (2012). https://doi.org/10.1007/s11060-012-0863-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-012-0863-y

Keywords

Search

Navigation